Dental Cleaning to Boost Weight-Loss and Metabolic Health in Obese Children on Semaglutide

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study builds on the MODERN program and compares two approaches over 12 months: dental cleaning plus oral hygiene instruction versus oral hygiene instruction alone, in children with class 2 or 3 obesity. Participants are drawn from the MODERN population and all receive semaglutide therapy as part of the parent study. The study aims to see if improved oral health from cleaning can enhance metabolic risk reduction beyond semaglutide alone, using standard clinical assessments. Exclusion criteria align with the parent MODERN trial, including recent dental interventions and medications that could affect periodontal response. Results will inform whether integrating dental care can provide additive benefits for pediatric obesity management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* participants from the ongoing Mitigation of Cardiovascular Disease Risks in Children with Extreme Obesity (MODERN) study (NCT06967389)
* Class 2 or 3 obesity (BMI =120% of the 95th percentile for age and sex)

Exclusion Criteria:

* Same exclusion as parent study.
* Planning to receive or complete dental services during the 12-month course of the study
* Ongoing orthodontic treatment
* Use of any anti-inflammatory medication (other than steroids) within 1 month prior to enrollment
* Currently taking medications that could influence the characteristics or response to periodontal treatment (e.g., use of immunosuppressants or steroids)
* Local or systemic antibiotic use within 15 days prior to enrollment or for \>10 days within the past 3 months
* History of bleeding disorders
* Professional dental prophylaxis or non-surgical periodontal therapy within the past 6 months

Where it's running

• University of Kentucky
  Lexington, Kentucky, United States Recruiting

Study contacts

• Principal investigator: Oelisoa Andriankaja, DDS, PhD — University of Kentucky
• Study coordinator: Oelisoa Mireille Andriankaja, DDS, MS, PhD
• Email: oelisoa.andriankaja@uky.edu
• Phone: 8595620597

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.